1、vnovotech-FEBRUARY 29,2024Cystic Fibrosis Global Clinical Trial Landscape(2024)Europe and North America lead in CF clinical trials,followed by Asia Pacific and a moderate contribution from the rest of the worldIn Europe,the UK and Germany lead,while the US dominates in North America,and Australia le

2、ads in Asia-PacificEurope show-cased quicker recruitment durations and faster patient recruitment ratesCystic Fibrosis(CF)is a hereditary autosomal recessive condition caused by CFTR gene mutations,afecting chloride transport and causing thick mucus buildup in organs,impairing their functionSome new

3、ly FDA-approved CFTR modulators include Kalydeco(ivacaftor),Orkambi(lumacaftor/ivacaftor),Symdeko(tezacaftor/ivacaftor),and TrikaftaThe market for CF treatment is diverse,featuring products from companies like Advanz Pharma Corp.Ltd.,Novartis AG,and Vertex Pharmaceuticals IncOngoing Phase III trials

4、 by Vertex Pharmaceuticals Inc.are advancing CF treatment with small molecule therapies targeting CFTRDidyouknow?In North America,the US leads with the highest CF patient population,while Canada shows a higher prevalence rateIn Europe,the UK leads in CF prevalence rates,while France,Germany,and Ital

5、y have higher CF patient populationsIn the Asia-Pacific region,Australia had a significant CF patient population,with New Zealand showing a high prevalence rate despite fewer patientsThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reprodu

6、ced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statemen